74531-82-1

Usage

Functional Groups

Imidazole ring, carboxylic acid, ester, methyl groups

Structure

The molecule consists of an imidazole ring with two methyl groups at the 1st and 5th positions, a carboxylic acid group at the 4th position, and an ethyl ester group attached to the carboxylic acid.

Appearance

It is likely a solid or oily liquid, depending on the conditions.

Solubility

Soluble in organic solvents like ethanol, methanol, and dichloromethane.

Stability

Stable under normal temperature and pressure, but sensitive to strong acids, bases, and oxidizing agents.

Reactivity

Can undergo reactions such as hydrolysis, esterification, and nucleophilic substitution due to the presence of the ester and imidazole functional groups.

Synthesis

It is synthesized by reacting 1H-imidazole-4-carboxylic acid with an excess of ethanol in the presence of an acid catalyst.

Applications

Used in organic synthesis, pharmaceutical research, and as a starting material for the synthesis of other complex molecules.

Medicinal Chemistry

Has potential applications in medicinal chemistry due to its imidazole ring structure, which is found in many bioactive molecules and pharmaceutical drugs.

Precautions

Handle with care, as it may be harmful if inhaled, ingested, or comes into contact with the skin. Use appropriate safety measures and personal protective equipment when handling 1H-Imidazole-4-carboxylic acid, 1,5-dimethyl-, ethyl ester.

Upstream product

• 51605-32-4 ethyl 4⁽⁵⁾-methylimidazole-5⁽⁴⁾-carboxylate 
• 74-88-4 methyl iodide 
• 51605-32-4 Ethyl 5-Methyl-4-imidazolecarboxylate 
• 1100817-23-9 ethyl 1,5-dimethyl-3-oxido-1H-imidazole-4-carboxylate 

Downstream Products

• 64689-22-1 1,4-dimethyl-5-hydroxymethylimidazole 
• 103968-59-8 ethyl 2-bromo-1,5-dimethyl-1H-Imidazole-4-Carboxylate 
• 129201-27-0 1,5-Dimethyl-4-phenylsulfanylmethyl-1H-imidazole 

Relevant academic research and scientific papers

INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

SUBSTITUTED SULPHONAMIDES FOR CONTROLLING ANIMAL PESTS

The present invention relates to the use of a compound of the general formula (I) in which M and D have the meanings given in the description for controlling animal pests.

Amino-Indolyl-Substituted Imidazolyl-Pyrimidines and Their Use as Medicaments

The invention relates to new amino-indole-substituted imidazolyl-pyrimidines of formula 1 wherein R1, R2, R3, R4 and R5 are defined as in claim 1 and pharmaceutically acceptable salts thereof and the use of these compounds for the preparation of a medicament for treating a disease selected from asthma, COPD, rheumatoid arthritis, specific lymphomas and specific diseases of the nervous system.

AMINO-INDOLYL-SUBSTITUTED IMIDAZOLYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS

The invention relates to new amino-indole-substituted imidazolyl-pyrimidines of formula (1), wherein R1, R2, R3, R4 and R5 are defined as in claim 1 and pharmaceutically acceptable salts thereof and the use of these compounds for the preparation of a medicament for treating a disease selected from asthma, COPD, rheumatoid arthritis, specific lymphomas and specific diseases of the nervous system

Novel farnesyl protein transferase inhibitors as antitumor agents

Disclosed are novel tricyclic compounds represented by the formula (1.0): and a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Synthesis and structure-activity relationships of new (5R,8R,10R)-ergoline derivatives with antihypertensive or dopaminergic activity

A series of new (5R,8R,10R)-ergoline derivatives was synthesized, and their antihypertensive and dopaminergic activities were tested in conscious spontaneously hypertensive rats and in rats with unilateral 6- hydroxydopamine-induced lesions of the substantia nigra. (5R,8R,10R)-6- Alkyl-8-ergolinemethanols, prepared from the corresponding ergolinecarboxylates, were converted to the tosylates, which were treated with various five-membered heterocycles containing nitrogen atoms to afford the new ergolines. (5R,8R,10R)-8-(1,2,4-Triazol-1-ylmethyl)-6-methylergoline (4s, maleate: BAM-1110) exhibited potent dopaminergic activity, about 18- fold greater than that of bromocriptine mesylate. (5R,8R,10R)-8-(1,2,4- Triazol-1-ylmethyl)-6-propylergoline (8b, fumarate: BAM-1602) showed extremely potent dopaminergic activity, being about 220 and 1.15 times more active than bromocriptine mesylate and pergolide mesylate, respectively. Several compounds exhibited potent antihypertensive activity. Structure- activity relationships for antihypertensive and dopaminergic activities are discussed.